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Abstract
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Lactobacillus reuteri NBF-2 when used in feed for cats at a minimum dose of
6 9 109 colony forming units (CFU) per animal and day. The additive is a preparation of viable cells of
L. reuteri DSM 32264. This species is considered by EFSA to be suitable for the qualiﬁed presumption
of safety (QPS) approach establishing safety for the target species and the environment. The active
agent fulﬁls the requirements of the QPS approach to the assessment of safety. Consequently, in the
absence of concerns form other components of the additives, Lactobacillus reuteri NBF-2 is presumed
safe for the target animals and the environment. Lactobacillus reuteri NBF-2 should be considered a
potential respiratory sensitiser. In the absence of data, the FEEDAP Panel cannot conclude on the
irritancy of the additive to skin and eyes or on its dermal sensitisation. The FEEDAP the Panel is not in
the position to conclude on the efﬁcacy of Lactobacillus reuteri NBF-2 for cats.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/2003 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from NBF Lanes s.r.l. for authorisation of
Lactobacillus reuteri NBF-2 (Lactobacillus reuteri DSM 32264) when used as a feed additive for cats
(category: zootechnical additives; functional group: gut ﬂora stabilisers).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
applications to the European Food Safety Authority (EFSA) as applications under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). The particulars and documents in
support of this application were considered valid by EFSA as of 31 May 2017.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, user and the environment and on the efﬁcacy of the product
Lactobacillus reuteri NBF-2 (L. reuteri DSM 32264), when used under the proposed conditions of use
(see Section 3.1.4).
1.2. Additional information
Lactobacillus reuteri NBF-2 is a preparation containing viable cells of L. reuteri DSM 32264. It has
not been previously authorised as a feed additive in the European Union.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier1 in support of the authorisation request for the use of Lactobacillus reuteri NBF-2 as a feed
additive.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the active agent in animal feed. The Executive Summary of the EURL
report can be found in Annex A.2
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Lactobacillus
reuteri NBF-2 is in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant
guidance documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012a), Technical
guidance: Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011, 2012b),
Guidance on studies concerning the safety of use of the additive for users/workers (EFSA FEEDAP
Panel, 2012b), Guidance on the assessment of bacterial susceptibility to antimicrobials of human and
veterinary importance (EFSA FEEDAP Panel, 2012c) and Guidance on the characterisation of
microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, 2018).
3. Assessment
The additive is a preparation of viable cells of L. reuteri DSM 32264 intended for use as a
zootechnical additive (gut ﬂora stabilisers) and cats to exert beneﬁcial effects in their gastrointestinal
tract leading to an increase in faecal consistency.
1 FEED dossier reference: FAD-2017-0002.
2 The full report is available on the EURL website: https://ec.europa.eu/jrc/en/eurl/feed-additives/evaluation-reports/fad-2017-
0002?search&form-return
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3.1. Characterisation
3.1.1. Characterisation of the active agent
L. reuteri DSM 32264 was isolated from cat faeces and is deposited in the Deutsche Sammlung von
Mikroorganismen und Zellkulturen (DSMZ) with the accession number DSM 32264.3 The applicant
declares that it has not been genetically modiﬁed.
Taxonomical identiﬁcation of the product strain as L. reuteri was established by morphological, and
biochemical properties (sugar fermentation pattern) and by analysing the partial sequence of the 16S
rRNA gene.4 For strain-speciﬁc identiﬁcation, randomly ampliﬁed polymorphic DNA (RAPD) was used.
The bacterial strain was tested for antibiotic susceptibility using broth microdilution techniques.5
The battery of antibiotics used included those recommended by EFSA (EFSA FEEDAP Panel, 2012c,
2018). The minimum inhibitory concentration (MIC) values for erythromcyin, clindamycin and
tetracycline were below or equal to the corresponding EFSA cut-off values, while those for the
remaining antibiotics were exceeded by one or more dilutions (i.e. ampicillin, gentamicin, streptomycin
and chloramphenicol by one dilution (4 vs 2 lg/mL, 16 vs 8 lg/mL, 128 vs 64 lg/mL and 8 vs 4 lg/
mL, respectively, and kanamycin by three dilutions (512 vs 64 lg/mL)). Exceedance of the cut-off
values by one dilution is considered to fall within the normal variation around the mean, and thus,
does not raise concerns for safety).
To elucidate the nature of the resistance to kanamycin, the applicant performed a whole genome
sequence analysis.6 The calculated genome size is 2.0 Mb. The genome was interrogated for the
presence of known genes coding for antimicrobial resistances by comparing with antimicrobial resistance
genes deposited in comprehensive antibiotic resistance database (CARD), antibiotic resistance gene
annotation database (ARG-ANNOT), antibiotic resistance genes database (ARDB) and MEGARes
database. No signiﬁcant matches were detected for genes coding for aminoglycoside resistance or for
other acquired genes coding for resistance to antimicrobial of clinical relevance. Consequently, the
resistance is assumed to be caused by mechanisms other than known acquired genes, and therefore has
minimal potential for horizontal spread. Consequently, it is not considered to be a hazard.
3.1.2. Characterisation of the additive
The active agent is grown in a sterilised medium, typical of those used for lactic acid bacteria, then
separated from the growth medium by centrifugation. Cryoprotectants (maltodextrin and L-cysteine),
are added and the cell mix is freeze-dried and ground. The active agent (10%) is then mixed with
maltodextrin and corn starch (90%) to meet the minimum speciﬁed concentration of 1 9 1011 colony
forming units (CFU)/g additive.
Analysis of ﬁve batches showed a mean value of 1.5 9 1011 CFU/g (range 1.3–1.7 9 1011 CFU/g).7
Microbial contamination is routinely monitored at various points in the manufacturing process and in
the ﬁnal product. Limits are set for yeasts and ﬁlamentous fungi (< 10 CFU/g), Escherichia coli (absent
in 1 g), Enterobacteriaceae (< 10 CFU/g), Salmonella spp. (absent in 25 g), Staphylococcus aureus
(absent in 1 g) and anaerobic sulﬁte reducers (< 10 CFU/g). Levels of aﬂatoxin M1 (< 0.5 lg/kg), lead
(< 3 ppm), mercury (< 0.1 ppm) and cadmium (< 1 ppm) are measured in raw materials once a year.
Compliance with action levels for all the mentioned impurities was conﬁrmed in three production
batches.8
The additive is a powder whose particle size distribution was determined using laser diffraction,
based on three batches.9 Results showed that (at 2 bars) 26% (v/v) of the additive consist of particles
with diameter lower than 50 lm and 5% lower than 10 lm.10 The dusting potential of the same three
3 Technical dossiers/Supplementary information May 2018/Question 1_Annex NBF-2 – Characterisation of the active agent (1).
4 Technical dossiers/Supplementary information May 2018/Question 2_Annexes NBF-2 – Characterisation of the active agent (2).
5 Technical dossier/Supplementary information May 2018/Question 3_Annexes NBF-2 – Characterisation of the active agent (3).
6 Technical dossier/Supplementary information May 2018/Question 3 – Annexes 1 (report 2018.TE.2249.1.3) and 2 (raw data).
and Supplementary information July 2018/Characterisation of the active agent – 1.
7 Technical dossiers/Supplementary information May 2018/Question 5_Annex NBF-2 – Characterisation of the additive (5).
8 Technical dossier/Section II/Annex II.7 and Supplementary information May 2018/Question 6_Annex NBF-2 - Characterisation
of the active additive (6).
9 Technical dossiers/Supplementary information May 2018/Question 7_Annex_NBF-2 - Characterisation of the active additive (7).
10 Technical dossier/Section II/Annex II.1.5a.
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batches, tested with a Heubach dustometer, showed a mean value of 10.2 g/m3, which is considered
high.11
3.1.3. Stability and homogeneity
The stability of the additive was tested when stored in aluminium packaging at 4°C and 25°C for a
period of 14 months and at 40°C for a period of 6 months.12 No losses were observed at 4°C, while
losses of 1 log or greater were observed after 11 months at 25°C and after 1 month at 40°C.
In the same experiment, the stability of the additives (three batches) was investigated when mixed
with a complementary cat food (described as consisting of microencapsulated tributyrate and red
orange polyphenols) at 9 9 1011 CFU/kg feed.13 Samples were stored at 25°C and 40°C for a period of
6 months. Losses of 1 log were observed after 3 months at 25°C while at 40°C losses of 2 log were
observed after 1 month.
To test the capacity of the additive (three batches) to be homogeneously incorporated into a dry
cat food (not described) according to the proposed conditions of use of 6 9 109 CFU/head per day
(i.e. mixing approximately 0.05 g of additive in 100 g of feed), 10 subsamples were collected and
subjected to lactobacilli determination.14 Counts showed a coefﬁcient of variation of 10%.
3.1.4. Conditions of use
Lactobacillus reuteri NBF-2 is intended for use in complete and complementary feed for cats (with a
moisture content < 14%) at a daily dose of 6 9 109 CFU per animal, which would approximately
equate to a minimum of 6 9 1010 and a maximum of 4.5 9 1011 CFU of L. reuteri DSM 32264/kg
complete feedingstuffs.13,15
3.2. Safety
3.2.1. Safety for the target species and the environment
Two studies were presented to support the safety of Lactobacillus reuteri NBF-2 for cats, but none
could be further considered due to inadequate study design and reporting (e.g. in one case no control
was included,16 and in the other, the end-points measured were only visual faecal scores and
frequency of illness17). Therefore, no conclusions can be drawn from these studies.
The bacterial species L. reuteri is considered by EFSA to be potentially suitable for the qualiﬁed
presumption of safety (QPS) approach to safety assessment (EFSA, 2007; EFSA BIOHAZ Panel, 2017).
This approach requires the identity of the strain to be conclusively established and evidence that it
does not show acquired resistance to antibiotics of human and veterinary importance. In the view of
the FEEDAP Panel, the identity of the active agent is established as L. reuteri. L. reuteri DSM 32264
showed phenotypic resistance to kanamycin. Interrogation of the whole genome sequence did not
evidence the presence of any known gene coding for resistance to antimicrobials of clinical relevance.
Consequently, the resistance is assumed to be caused by mechanisms other than known acquired
genes, with a minimal potential for horizontal spread. Therefore, the antibiotic resistance qualiﬁcation
has been met and the strain can be presumed safe for the target species and the environment. Since
no concerns are expected from the other components of the additives, Lactobacillus reuteri NBF-2 is
also considered safe for target animals and the environment.
3.2.2. Safety for the user
No data on skin/eye irritation, skin sensitisation or inhalation toxicity have been provided. The
dustiness of the preparations tested indicated a potential for users to be exposed via inhalation. A
signiﬁcant fraction of the products consist of ﬁne particles that have the potential to reach the alveoli
11 Technical dossier FAD-2017-0002/Supplementary information May 2018/Question 7_Annexes NBF-2- Characterisation of the
active additive (7a, b and c).
12 Technical dossiers/Supplementary information May 2018/Question 8_Annex_NBF-2- Characterisation of the active additive (8).
13 Technical dossiers/Supplementary information May 2018/Questions 10 and 9.
14 Technical dossiers/Supplementary information may 2018/Question 10_ Annex_ NBF-1- Characterisation of the active additive
(10) and Question 9_Annex NBF-2 - Characterisation of the active additive (9).
15 Technical dossier/Supplementary information May 2018/Question 11.
16 Technical dossier FAD-2017-0001/Section III/Annex III.1.
17 Technical dossier FAD-2017-0002/Supplementary information may 2018/Question 12_Annex NBF-2 – Efﬁcacy (12) Efﬁcacy and
tolerance study (3).
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when inhaled. Given the proteinaceous nature of the active agent, the additive should be considered a
potential respiratory sensitiser. In the absence of data, the FEEDAP Panel cannot conclude on the
irritancy of Lactobacillus reuteri NBF-1 to skin and eyes or on its dermal sensitisation.
3.3. Efﬁcacy for cats
The additive is a preparation of viable cells of L. reuteri DSM 32264 intended for use as a
zootechnical additive (gut ﬂora stabilisers) in feed for cats to exert beneﬁcial effects in their
gastrointestinal tract, leading to an increase in faecal consistency.
Five efﬁcacy studies were conducted to support the efﬁcacy of Lactobacillus reuteri NBF-2 for cats.
However, none could be further considered due to weaknesses in the experimental design and/or
reporting. In one18 case, due to its short duration (15 days), inclusion of sick animals and insufﬁcient
reporting, and in a second case,19 because the study involved animals with poor health.20 In the
remaining three cases21,22,23 the experiments involved cats kept in individual houses with trained
caretakers, with faecal consistency as the only end-point, subjectively analysed by laboratory
personnel. The studies were described as double-blind experiments, declaring that the experimental
foods were the only source of nutrients and energy for cats. Additionally, the study reports did not
include any information, among other, regarding the methodology applied for the randomisation of the
treatments, the blinding and its maintenance during the whole experiment, the details regarding food
ingestion by cats and any other source of feed they might have had, or the potential deviations from
the protocol. Therefore, no conclusions can be drawn from these studies.
3.3.1. Conclusions on efﬁcacy for cats
The FEEDAP Panel is not in the position to conclude on the efﬁcacy of Lactobacillus reuteri NBF-2
for cats.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation24 and Good
Manufacturing Practice.
4. Conclusions
The active agent fulﬁls the requirements of the QPS approach to the assessment of safety.
Consequently, in the absence of concerns from other components of the additive Lactobacillus reuteri
NBF-2 is presumed safe for the target animals and the environment.
Lactobacillus reuteri NBF-2 should be considered a potential respiratory sensitiser. In the absence of
data, the FEEDAP Panel cannot conclude on the irritancy potential of the additive to skin and eyes or
on its dermal sensitisation potential.
The FEEDAP the Panel is not in the position to conclude on the efﬁcacy of Lactobacillus reuteri
NBF-2 for cats.
Documentation provided to EFSA
1) Lactobacillus reuteri NBF-2. January 2017. Submitted by NBF Lanes s.r.l.
2) Lactobacillus reuteri NBF-2. Supplementary information. May 2018. Submitted by NBF Lanes
s.r.l.
18 Technical dossier FAD-2017-0002/Section III/Annex IV.1
19 Technical dossier FAD-2017-0002/Supplementary information May 2018/Annex NBF-2 – Efﬁcacy (12)/Efﬁcacy and tolerance
study (3).
20 The frequencies of sick animals in each treatment group were: 9/10 in the control, 7/8 in the 19 and 6/7 in the 1009 dose
groups.
21 Technical dossier FAD-2017-0002/Supplementary information May 2018/Question 12_Annex NBF-2 – Efﬁcacy (12)/Efﬁcacy
study (1) and Supplementary information July 2018/Efﬁcacy and Annex 1a.
22 Technical dossier FAD-2017-0002/Supplementary information May 2018/Question 12_Annex NBF-2 – Efﬁcacy (12)/Efﬁcacy
study (2) and Supplementary information July 2018/Efﬁcacy and Annex 1b.
23 Technical dossier FAD-2017-0002/Supplementary information July 2018/Efﬁcacy – 2/New efﬁcacy NBF-2.
24 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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3) Lactobacillus reuteri NBF-2. Supplementary information. July 2018. Submitted by NBF Lanes s.r.l.
4) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods(s) of Analysis for Lactobacillus reuteri NBF-2.
5) Member States comments.
Chronology
Date Event
3/1/2017 Dossier received by EFSA
19/1/2017 Reception mandate from the European Commission
31/5/2017 Application validated by EFSA – Start of the scientiﬁc assessment
4/7/2017 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: characterisation, safety and
efﬁcacy
18/9/2017 Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives
13/2/2018 Clariﬁcation teleconference during risk assessment with the applicant according to the “EFSA’s
Catalogue of support initiatives during the life-cycle of applications for regulated products”
14/5/2018 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
07/6/2018 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended Issues: efﬁcacy
13/7/2018 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
24/10/2018 Comments received from Member States
27/11/2018 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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ARDB antibiotic resistance genes database
ARG-ANNOT antibiotic resistance gene annotation database
CARD comprehensive antibiotic resistance database
CFU colony forming unit
DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen
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EURL European Union Reference Laboratory
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
MIC minimum inhibitory concentration
PFGE pulsed ﬁeld gel electrophoresis
RAPD randomly ampliﬁed polymorphic DNA
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Method(s) of
Analysis for Lactobacillus reuteri NBF-2
In the current application authorisation is sought under Article 4(1) for Lactobacillus reuteri NBF-2
(DSM 32264) under the category/functional group 4(b) ‘zootechnical additives’/‘gut ﬂora stabilisers’,
according to Annex I of Regulation (EC) No 1831/2003. Authorisation is sought for the use of the feed
additive for cats.
According to the Applicant, the feed additive contains as active substance viable cells of the strain
Lactobacillus reuteri NBF-2 (DSM 32264). The feed additive is to be marketed as a lyophilised powder
containing a minimum Lactobacillus reuteri NBF-2 (DSM 32264) content of 1011 Colony Forming Unit
(CFU)/g. The feed additive is intended to be administered as complementary feedingstuffs with a
content ranging from 1 x 109 to 1 x 1010 CFU/kg or to be mixed with usual feed.
For the identiﬁcation of Lactobacillus reuteri NBF-2 (DSM 32264) the Applicant applied 16S rRNA
gene sequence analysis and random ampliﬁed polymorphic DNA analysis. The EURL recommends
instead for ofﬁcial control Pulsed Field Gel Electrophoresis (PFGE), a generally recognised methodology
for genetic identiﬁcation of bacterial strains.
For the enumeration of Lactobacillus reuteri NBF-2 (DSM 32264) in the feed additive and
feedingstuffs, the Applicant submitted the ring-trial validated spread plate method EN 15787. Based on
the performance characteristics available, the EURL recommends this method for ofﬁcial control.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005, as last
amended by Regulation (EU) 2015/1761) is not considered necessary.
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